Clinical Trial

XS-03 in Combination With FOLFOX or FOLFIRI and Bevacizumab for Treatment of Metastatic Colorectal Cancer Patients With RAS Mutation

Study acronym: XS-03-II201
Enrolling by Invitation Phase 1/2
View on ClinicalTrials.gov →
Summary
XS-03 in combination with FOLFOX or FOLFIRI and Bevacizumab for treatment of metastatic colorectal cancer patients with RAS mutation
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-04-17.
Status change: Not Yet Recruiting → Enrolling by Invitation 2025-08-26
Trial Details
NCT Number NCT06936527
Lead Sponsor NovaOnco Therapeutics Co., Ltd.
Conditions Colorectal Cancer, Metastatic Colorectal Cancer With RAS Mutation
Enrollment 102 participants
Start Date 2025-05-23
Primary Completion 2028-04-30 (estimated)
Study Completion 2028-07-30 (estimated)
Updated on ClinicalTrials.gov 2025-09-03